TABLE 3.

Dose recommendations based on the results from this study compared with the WHO revised dosages^a

Drug	Target (value)	Wt band (kg)	NAT2 genotype	Dose achieving 90% TA		WHO revised dosage (mg) in:
				mg	mg/kg	2010	2014
Rifampin	Cmax (3.01 μg/ml)	5–7		120	18.6	120	60–120
		8–14		180	14.4	180	120–180
		15–20		240	13.6	300	240–300
		21–30		240	10.7	420	300
	AUC0–24 (3.70 mg · h/liter)	5–7		60	9.3	120	60–120
		8–14		60	4.8	180	120–180
		15–20		120	6.8	300	240–300
		21–30		120	5.4	420	300
Isoniazid	Cmax (3 μg/ml)	5–7	All	60	9.3	90	30–60
		8–14	All	90	7.2	120	60–90
		15–20	All	120	6.8	210	120–150
		21–30	All	210	9.4	270	150
	AUC0–24 (11.95 mg · h/liter)	5–7	Nonslow	120	18.5	90	30–60
		8–14	Nonslow	210	17.1	120	60–90
		15–20	Nonslow	270	14.8	210	120–150
		21–30	Nonslow	270	12.2	270	150
		5–7	Slow	60	9.4	90	30–60
		8–14	Slow	90	7.2	120	60–90
		15–20	Slow	120	6.9	210	120–150
		21–30	Slow	210	8.7	270	150
Pyrazinamide	Cmax (20 μg/ml)	5–7		300	46.5	150	150–300
		8–14		450	36.0	300	300–450
		15–20		450	25.4	450	600–750
		21–30		600	26.8	800	750
	Cmax (38.1 μg/ml)	5–7		450	69.8	150	150–300
		8–14		800	64.0	300	300–450
		15–20		900	50.8	450	600–750
		21–30		1,050	46.9	800	750
Ethambutol	Cmax (2 μg/ml)	5–7		400	62.0	100	100–200
		8–14		550	44.0	200	200
		15–20		550	31.1	300	300–400
		21–30		550	24.6	550	400

^aNAT2, N-acetyltransferase 2 gene; TA, target attainment.